News headlines about Thoratec (NASDAQ:THOR) have been trending somewhat negative this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Thoratec earned a daily sentiment score of -0.22 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.8313325777193 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at

Thoratec Company Profile

Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).

Insider Buying and Selling by Quarter for Thoratec (NASDAQ:THOR)

Receive News & Ratings for Thoratec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec and related companies with's FREE daily email newsletter.